Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 486 of 5804
-
Engineered immune cells take on rare autoimmune disease in kids
Disease control Recruiting nowThis is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset systemic sclerosis
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail aims to shrink stomach tumors in Mid-Stage trial
Disease control OngoingCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan (ABBV-400) is given in combination with Fluorouracil, Leucovorin, and…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Radiation boost may tame brain spread in lung cancer
Disease control Recruiting nowThe researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC. The researchers will also look at how the study intervention impacts part…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to slow advanced breast cancer in BRCA patients
Disease control Recruiting nowTrial design: Phase II, prospective, multi-center, randomized, open label, parallel group study in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with 2:1 randomization into Arm A (olaparib + elacestrant) or arm B (o…
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can breathing pure oxygen boost stroke recovery?
Disease control Recruiting nowThe primary objective of this study is to estimate the efficacy and safety of NBO on 3-month functional outcome after acute ischemic stroke
Phase: PHASE3 • Sponsor: Capital Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Smart armbands could catch strokes before doctors do
Diagnosis Recruiting nowThis trial aims to demonstrate that the Neuralert Monitoring System will detect strokes before they would be identified by current standard of care. Each patient will be monitored for up to five days, depending on device connectivity or battery duration. Each monitoring session w…
Phase: NA • Sponsor: Neuralert Technologies LLC • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
CAR-T cells take on progressive MS: early trial launches
Disease control Recruiting nowThis is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control Recruiting nowThis is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Phase: PHASE2 • Sponsor: Faeth Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
30,000 volunteers sought to catch pancreatic cancer early
Knowledge-focused Recruiting nowThis study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cure…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New hope for myeloma patients too old for transplant?
Disease control Recruiting nowThis study will evaluate efficacy and tolerability of iberdomide, bortezomib, dexamethasone and isatuximab on demand administered in combination for newly diagnosed transplant-ineligible multiple myeloma patients.
Phase: PHASE2 • Sponsor: Canadian Myeloma Research Group • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New mRNA drug hopes to help cystic fibrosis patients who Can't use current therapies
Disease control Recruiting nowARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
Phase: PHASE2 • Sponsor: Arcturus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental antibody cocktail takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be tes…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Pill-Form fungus fighter takes on deadly candida
Disease control Recruiting nowThe purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. T…
Phase: PHASE3 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immunotherapy duo takes on cervical cancer in new trial
Disease control OngoingMulticenter, open-label, randomized, seeking signal (non-comparative), Phase II aiming to assess the clinical activity of the combination relatlimab + nivolumab in locally advanced cervical cancer eligible to standard CCRT
Phase: PHASE2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New anxiety pill shows promise in Late-Stage trial
Symptom relief OngoingA Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Phase: PHASE3 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New HIV pill dose for kids shows promise in african study
Disease control CompletedThis study aims to find out whether treating children living with HIV with three anti-HIV medicines, dolutegravir (DTG), emtricitabine (FTC) and tenofovir alafenamide (TAF), with a novel dose ratio will achieve adequate drug concentrations and is safe. The optimal DTG/FTC/TAF dos…
Phase: PHASE2 • Sponsor: PENTA Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug duo takes on tough lymphoma
Disease control Recruiting nowTo assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Blood test may spot pancreatic cancer early, study hopes
Diagnosis Recruiting nowThe challenge for medical oncology is to develop plasma biomarkers that can detect the influence of the stroma on diagnosis, prognosis and response to chemotherapy. Today, there is no validated blood test to help diagnose pancreatic cancer (PDAC). The search for blood biomarkers…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New hope for ulcerative colitis: phase 3 trial launches
Disease control Recruiting nowThis Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Blood test may personalize esophageal cancer therapy
Disease control Recruiting nowEsophageal squamous cell carcinoma (ESCC) continues to exhibit high incidence and mortality rates in China, with the majority of patients diagnosed at middle to advanced stages. Concurrent chemoradiotherapy (CCRT) is the standard treatment for unresectable locally advanced ESCC. …
Phase: NA • Sponsor: The Central Hospital of Lishui City • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC